Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 973-980

  Cluny, Nina L ^a   Keenan, Catherine M ^a   Duncan, Marnie ^a   Fox, Alyson ^b   Lutz, Beat ^c   Sharkey, Keith A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; DEXTRAN SULFATE; NAPHTHALEN 1 YL (4 PENTYLOXYNAPHTHALEN 1 YL)METHANONE; SAB 378; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; NAPHTHALEN-1-YL-(4-PENTYLOXYNAPHTHALEN-1-YL)METHANONE; NAPHTHALENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON MOTILITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; INFLAMMATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPPER GASTROINTESTINAL TRACT; AGONISTS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLON; DRUG EFFECTS; MOTOR ACTIVITY; PATHOLOGY;

ANIMALS; COLITIS; COLON; DEXTRAN SULFATE; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NAPHTHALENES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TRINITROBENZENESULFONIC ACID;

EID: 77956260156     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169946     Document Type: Article

References (39)

1. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, and Zimmer A (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396:141-149.
2. Colombo G, Agabio R, Lobina C, Reali R, and Gessa GL (1998) Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 344:67-69.
3. Compton DR, Gold LH, Ward SJ, Balster RL, and Martin BR (1992) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126.
4. Coutts AA, Irving AJ, Mackie K, Pertwee RG, and Anavi-Goffer S (2002) Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448:410-422.
5. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, and Di Marzo V (2006) Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20:568-570.
6. De Petrocellis L and Di Marzo V (2009) An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 23:1-15.
7. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, Patel KD, Pittman QJ, and Sharkey KA (2008) Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide- treated rats. Am J Physiol Gastrointest Liver Physiol 295:G78-G87.
8. Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, et al. (2007) Naphthalen-1-yl-(4- pentyloxynaphthalen- 1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 50:3851-3856.
9. Engel MA, Kellermann CA, Rau T, Burnat G, Hahn EG, and Konturek PC (2008) Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide. J Physiol Pharmacol 59:673-689.
10. Fujino K, Takami Y, de la Fuente SG, Ludwig KA, and Mantyh CR (2004) Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J Gastrointest Surg 8:842-847; discussion 847-848.
11. Furness JB (2006) The Enteric Nervous System. Blackwell Publishing, Malden, MA.
12. Gardin A, Kucher K, Kiese B, and Appel-Dingemanse S (2009) Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety. Drug Metab Dispos 37:827-833.
13. Ghia JE, Blennerhassett P, El-Sharkawy RT, and Collins SM (2007) The protective effect of the vagus nerve in a murine model of chronic relapsing colitis. Am J Physiol Gastrointest Liver Physiol 293:G711-G718.
14. Giuliani D, Ottani A, and Ferrari F (2000) Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats. Eur J Pharmacol 391:275-279. (Pubitemid 30154095)
15. Herkenham M (1992) Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann NY Acad Sci 654:19-32.
16. Izzo AA and Sharkey KA (2010) Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126:21-38.
17. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, Esposito G, Mascolo N, Di Marzo V, and Capasso F (2001) Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134:563-570.
18. Izzo AA, Mascolo N, Borrelli F, and Capasso F (1999a) Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 359:65-70.
19. Izzo AA, Mascolo N, Capasso R, Germanò MP, De Pasquale R, and Capasso F (1999b) Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol 360:221-223.
20. Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, and Capasso F (2000) Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 129:1627-1632.
21. Kihara N, de la Fuente SG, Fujino K, Takahashi T, Pappas TN, and Mantyh CR (2003) Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 52:713-719.
22. Kimball ES, Schneider CR, Wallace NH, and Hornby PJ (2006) Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291:G364-G371.
23. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, Digavalli SV, and Hornby PJ (1999) Δ9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 371:187-196.
24. Kulkarni-Narla A and Brown DR (2000) Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302:73-80.
25. Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, and Manara L (2002) Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur J Pharmacol 450:77-83.
26. Little PJ, Compton DR, Johnson MR, Melvin LS, and Martin BR (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247:1046-1051.
27. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534.
28. Mascolo N, Izzo AA, Ligresti A, Costagliola A, Pinto L, Cascio MG, Maffia P, Cecio A, Capasso F, and Di Marzo V (2002) The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 16:1973-1975.
29. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, and Lutz B (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209.
30. Mathison R, Ho W, Pittman QJ, Davison JS, and Sharkey KA (2004) Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide- treated rats. Br J Pharmacol 142:1247-1254.
31. McCafferty DM, Wallace JL, and Sharkey KA (1997) Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol Gastrointest Liver Physiol 272:G272-G280.
32. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, and Capasso F (2002) Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123:227-234.
33. Shook JE and Burks TF (1989) Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 249:444-449.
34. Smith SR, Denhardt G, and Terminelli C (2001) The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur J Pharmacol 432: 107-119.
35. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE, Lutz B, Göke B, et al. (2008) Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 86:925-936.
36. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, and Sharkey KA (2009) Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 15:1678-1685.
37. Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, Kretz O, Galli B, and Porter CJ (2009) Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res 26:1486-1495.
38. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329-332.
39. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, and Sharkey KA (2001) Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121:767-774.